IDO Proteins, Antibodies, cDNA Clones Research Reagents

IDO1 (Indoleamine 2,3-Dioxygenase 1, also known as IDO; INDO; IDO-1), located on 8p11.21, is a Protein Coding gene. The gene produces a 45326 Da protein composed of 403 amino acids. IDO1 catalyzes the degradation of the essential amino acid L-tryptophan to N-formyl-kynurenine. IDO1 suppresses adaptive T-cell immunity by catabolizing tryptophan from the cellular microenvironment. The related pathways of IDO1 include Histidine, lysine, phenylalanine, tyrosine, proline, and tryptophan catabolism, and superpathway of tryptophan utilization.

IDO Protein (2)

    IDO Antibody (6)

      IDO cDNA Clone (43)

      NM_002164.4

      克隆载体 cDNA 产品

      In lentiviral vector

      NM_001293690.1

      IDO qPCR Primer (1)

      IDO 分子背景

      Indoleamine 2,3-dioxygenase-1, also known as Indoleamine-pyrrole 2,3-dioxygenase, IDO1, and IDO, is a member of the indoleamine 2,3-dioxygenase family. IDO1 / IDO and tryptophan 2,3-dioxygenase (TDO) are tryptophan-degrading enzymes that catalyze the first step in tryptophan catabolism via the kynurenine pathway. TDO is widely distributed in both eukaryotes and bacteria. In contrast, IDO has been found only in mammals and yeast. In 27, a third enzyme, indoleamine 2,3-dioxygenase-2 (IDO2), was discovered. IDO2 is found not only in mammals but also in lower vertebrates. IDO1 / IDO is an immunosuppressive molecule inducible in various cells. IDO1 / IDO catalyzes the cleavage of the pyrrole ring of tryptophan and incorporates both atoms of a molecule of oxygen. It mediates oxidative cleavage of tryptophan, an amino acid essential for cell proliferation and survival. IDO1 / IDO inhibition is proposed to have therapeutic potential in immunodeficiency-associated abnormalities, including cancer. The IDO pathway is activated in multiple tumor types. Selective inhibition of IDO1 may represent an attractive cancer therapeutic strategy via up-regulation of cellular immunity. IDO1 / IDO is an enzyme that suppresses adaptive T-cell immunity by catabolizing tryptophan from the cellular microenvironment. Inhibition of IDO pathway might enhance the efficacy of immunotherapeutic strategies for cancer.

      IDO 参考文献

      • Barnes NA. et al., 2009, J Immunol. 183 (9): 5768-77.
      • Yuasa HJ. et al., 2009, Comp Biochem Physiol B Biochem Mol Biol. 153 (2): 137-44.
      • L b S. et al., 2009, Cancer Immunol Immunother. 58 (1): 153-7.
      • Liu,X. et al., 2010, Blood.115 (17): 3520-30.
      • Sun,T. et al., 2010, Mol Cell Biochem. 342 (1-2): 29-34.
      • Kiank C. et al., 2010, PLoS One. 5 (7): e11825.

      Note: Flag® is a registered trademark of Sigma Aldrich Biotechnology LP. It is used here for informational purposes only.